

This is a repository copy of Diagnosing prostate cancer in asymptomatic patients.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/187600/

Version: Accepted Version

Article:

Bradley, SH orcid.org/0000-0002-2038-2056, Funston, G, Jones, D et al. (1 more author) (2022) Diagnosing prostate cancer in asymptomatic patients. BMJ, 377. e071076. e071076-e071076. ISSN 1759-2151

https://doi.org/10.1136/bmj-2022-071076

© 2022, BMJ Publishing Group Ltd. This manuscript version is made available under the CC BY-NC 4.0 license https://creativecommons.org/licenses/by-nc/4.0/

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

Prostate cancer diagnosis in asymptomatic patients

Given the uncertain benefits and the need to prioritise resources that deliver improvements in cancer outcomes, caution is still required on promoting testing for prostate cancer in asymptomatic patients

The pandemic has disrupted cancer diagnosis and treatment in health systems worldwide. In response, patients at risk of cancer have been encouraged to present to health services to support prompt diagnosis.(1) In England, this has included a collaboration between the NHS and Prostate Cancer UK to 'find the 14,000 men' estimated to have not yet started treatment for prostate cancer, because of the pandemic.(2)

Challenges in asymptomatic detection

The heterogeneous behaviour of prostate cancers along with the relatively poor performance of the blood test prostate specific antigen (PSA) in identifying clinically significant disease, remain obstacles to implementing beneficial early diagnosis strategies.(3, 4) A systematic review reported that screening with PSA has have little or no effect on prostate cancer mortality (incidence rate ratio: 0.96, 95% confidence intervals: 0.85 - 1.08) and can, at best, prevent one prostate cancer death for every 1,000 patients over the course of 10 years.(5)

The utilisation of multi-parametric magnetic resonance imaging has the potential to ameliorate some of the harms of screening, by reducing the proportion of patients with an elevated PSA who require biopsy and, thereby, limiting biopsy related complications including sepsis, urinary incontinence and erectile dysfunction.(6) These developments, in combination with advances in the identification of men who have higher genetic risk, may in time tip the balance of benefits and harms in favour of screening.(7) In the meantime, routine screening is not recommended by either the UK's National Screening Committee (NSC) nor the United States Preventive Service Task Force. In both countries asymptomatic individuals can opt for PSA testing, after exploring the benefits and harms with a clinician.(8-10) The number of PSA tests performed has increased markedly over the past two decades (11, 12), contributing to higher incidence but with uncertain benefits since a large proportion of cases probably constitute overdiagnosis.(13) Given these uncertainties, UK General Practitioners are advised that 'PSA testing should not be offered to asymptomatic people', unless specifically requested.(14)

A departure

NHS England's bid to 'find the 14,000 men' appears to depart from this cautious approach. The campaign has warned that patients 'shouldn't wait for symptoms' and encourages men to use a 'risk checker'. This informs men aged over 45 with particular risk factors (black or mixed black ethnicity or a first degree relative who has had prostate cancer) and *all* men aged over 50, that they 'may be at higher risk' and suggests arranging a GP appointment to discuss this risk. Further prompts explain that the 'first step to finding early prostate cancer is a PSA test'.(15) Urging men to use the 'risk checker', NHS England's national clinical director for cancer said "prostate cancer often doesn't show any symptoms at an early stage, so don't delay – check your risk now. The simple check could be lifesaving."

Questions raised

Arguably this messaging is consistent with the established principle of allowing patients to decide for themselves on PSA testing, and the 'risk checker' does provide some valuable information for patients. However, the apparent presumption of benefit in detecting asymptomatic disease could lead patients to believe that the NHS is promoting screening.

For GPs, ensuring patients understand the pros and cons of PSA testing and arrive at a decision that is consistent with their own values and priorities is vital, but shared decision making discussions are complex and time-consuming.(16) The quality of such discussions is likely to be highly variable and, particularly where patients have a firm expectation of having a PSA test at the outset, GPs may find it expedient to accede without fully exploring the possible consequences.(17) Encouraging all asymptomatic men over 50 to book a GP appointment to discuss their risk has resource implications, which resonates with concerns raised about a 'heart age test' which encouraged those aged over 30 to obtain a blood test for cholesterol.(18)

Other practical questions for doctors and patients abound. If patients choose screening, after what interval should they consider repeat testing? Should asymptomatic patients consider having digital rectal examination along with PSA? What resources should guide shared decision making and is there a role for risk calculators?(19) Should GPs counsel those aged under 50 who have been flagged as higher risk by the 'risk checker' that PSA is not supported by official guidance for their age group?(10)

Greater clarity, consistency and support required

Information to patients should convey that while PSA testing is available upon request for over 50s it is not currently recommended, and why. If asymptomatic over-45s in certain risk categories should be eligible for PSA testing this needs to be stated in the national guidance which has not been updated for over six years.(10) GPs and patients need practical up-to-date guidance on PSA testing, including recommended evidence-based tools and resources to support shared decision making. If a 'risk checker' tool is to be promoted as part of an early detection strategy it is vital that it be evidence based and subject to appropriate evaluation. Meanwhile, efforts must continue to focus on ensuring prompt diagnosis of symptomatic patients and generating sufficient evidence for a systematic screening programme to satisfy the NSC of its clinical and cost effectiveness.

Stephen H. Bradley- General Practitioner and Clinical Research Fellow, University of Leeds Garth Funston- ST3 in General Practice and NIHR Academic Clinical Fellow, University of Manchester Daniel Jones – General Practitioner and NIHR Academic Clinical Lecturer, University of Leeds Jessica Watson – General Practitioner and NIHR Academic Clinical Lecturer, University of Bristol

Competing Interests

Stephen Bradley: I receive funding for doctoral research from the CanTest collaborative (Cancer Research UK). I am clinical lead for cancer for NHS Leeds clinical commissioning group. The publication costs of a collection of essays on health inequalities which I co-edited for the Fabian

Society (a political think tank) was funded by the Association of the British Pharmaceutical Industry and Lloyds Pharmacies, I received no direct funding or payment for this. I sit on the NIHR's Health Services & Delivery research prioritisation committee (unpaid aside from reimbursement of travel expenses). I am a co-investigator on a study which is funded by Yorkshire Cancer Research (Patientcentred models for surveillance and support of cancer survivors with bowel and breast cancer). I have previously received funding from the Mason Medical Foundation to undertake a study on chest x-ray and lung cancer diagnosis.

Garth Funston: I am Co-Principal Investigator on a National Institute for Health Research grant (Primary care models for the detection of clinically significant prostate cancer: the ProsDetect study, NIHR202734).

The other authors have no interests to declare.

Funding

Stephen H. Bradley is funded by the multi-institutional CanTest Collaborative which is funded by Cancer Research UK (C8640/A23385).

Garth Funston is funded by an NIHR Academic Clinical Fellowship in General Practice. The opinions presented are those of the authors alone and do not necessarily reflect those of the authors' employers or funders.

Contributorship statement & guarantor

The editorial was conceived by Stephen Bradley who authored the first draft of the manuscript. All authors contributed to subsequent revisions of the manuscript. The guarantor is Stephen Bradley

Copyright statement/ licence for publication

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the <u>author licence</u>), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which licence will apply to this Work are set out in our licence referred to above." 1. NHS chief urges people to come forward for life saving cancer checks ahead of new campaign: NHS England; [updated 14 Aug 2021. Available from:

https://www.england.nhs.uk/2021/08/nhs-chief-urges-people-to-come-forward-for-life-savingcancer-checks-ahead-of-new-campaign/.

2. Find the 14,000 men Prostate Cancer UK; [Available from:

https://prostatecanceruk.org/prostate-information/risk-campaign.

3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. 2019;144(8):1941-53.

4. Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Medicine. 2022;20(1):54.

5. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. 2018;362:k3519.

6. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017;389(10071):815-22.

7. Genetics of Prostate Cancer: National Cancer Institute; [Available from:

https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq.

8. Prostate Cancer: UK National Screening Committee; [Available from: <u>https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/</u>.

9. Force UPST. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901-13.

10. Prostate cancer risk management programme: Public Health England; [Available from: https://www.gov.uk/guidance/prostate-cancer-risk-management-programme-overview.

11. O'Sullivan JW, Stevens S, Hobbs FDR, Salisbury C, Little P, Goldacre B, et al. Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. 2018;363:k4666.

12. Young GJ, Harrison S, Turner EL, Walsh El, Oliver SE, Ben-Shlomo Y, et al. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. 2017;7(10):e017729.

13. Oke JL, O'Sullivan JW, Perera R, Nicholson BD. The mapping of cancer incidence and mortality trends in the UK from 1980–2013 reveals a potential for overdiagnosis. Scientific Reports. 2018;8(1):14663.

14. How should I assess a person with suspected prostate cancer? : NICE Clinical Knowledge Summaries; 2022 [Available from: <u>https://cks.nice.org.uk/topics/prostate-</u>cancer/diagnosis/assessment/.

15. Prostate Cancer UK check your risk in 30 seconds [Available from: <u>https://prostatecanceruk.org/risk-checker.html</u>.

16. Stiggelbout AM, Weijden TVd, Wit MPTD, Frosch D, Légaré F, Montori VM, et al. Shared decision making: really putting patients at the centre of healthcare. 2012;344:e256.

17. Han PKJ, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, et al. National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med. 2013;11(4):306-14.

18. Bonner C, McKinn S, McCaffrey K, Glasziou P, Irwig L, Doust J, et al. Is the NHS 'Heart Age Test' too much medicine? 2019;69(688):560-1.

19. Prostate Cancer Prevention Trial Risk Calculator Version 2.0 [Available from: https://riskcalc.org/PCPTRC/.